Zacks Research Issues Positive Outlook for BMRN Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Zacks Research raised their Q1 2025 earnings per share (EPS) estimates for BioMarin Pharmaceutical in a note issued to investors on Tuesday, November 19th. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings per share of $0.60 for the quarter, up from their prior forecast of $0.59. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.47 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s Q2 2025 earnings at $0.68 EPS, Q1 2026 earnings at $0.76 EPS, Q2 2026 earnings at $0.83 EPS and FY2026 earnings at $3.36 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.78 by ($0.23). BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%. The company had revenue of $746.00 million for the quarter, compared to the consensus estimate of $703.37 million. During the same quarter in the previous year, the business earned $0.26 EPS. The company’s quarterly revenue was up 28.4% on a year-over-year basis.

Several other research firms also recently weighed in on BMRN. JPMorgan Chase & Co. decreased their price objective on BioMarin Pharmaceutical from $110.00 to $109.00 and set an “overweight” rating for the company in a report on Wednesday, October 30th. Royal Bank of Canada restated a “sector perform” rating and set a $80.00 target price on shares of BioMarin Pharmaceutical in a research note on Wednesday, October 30th. Sanford C. Bernstein cut their price target on shares of BioMarin Pharmaceutical from $116.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, September 17th. William Blair cut BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 30th. Finally, Canaccord Genuity Group decreased their target price on shares of BioMarin Pharmaceutical from $93.00 to $84.00 and set a “hold” rating for the company in a research report on Wednesday, October 30th. Seven equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $94.20.

BioMarin Pharmaceutical Trading Up 1.3 %

NASDAQ BMRN opened at $64.26 on Thursday. BioMarin Pharmaceutical has a 12 month low of $61.15 and a 12 month high of $99.56. The stock has a market cap of $12.25 billion, a PE ratio of 38.48, a PEG ratio of 0.61 and a beta of 0.31. The company’s 50-day moving average price is $68.25 and its 200-day moving average price is $78.47. The company has a current ratio of 4.27, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11.

Insider Activity

In other news, EVP Charles Greg Guyer sold 5,278 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total transaction of $350,300.86. Following the transaction, the executive vice president now owns 68,909 shares of the company’s stock, valued at approximately $4,573,490.33. The trade was a 7.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.85% of the company’s stock.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Several institutional investors and hedge funds have recently bought and sold shares of BMRN. Acadian Asset Management LLC lifted its holdings in shares of BioMarin Pharmaceutical by 32.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,537 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 625 shares during the last quarter. UniSuper Management Pty Ltd lifted its holdings in shares of BioMarin Pharmaceutical by 107.7% in the 1st quarter. UniSuper Management Pty Ltd now owns 2,700 shares of the biotechnology company’s stock valued at $236,000 after purchasing an additional 1,400 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in shares of BioMarin Pharmaceutical in the first quarter valued at approximately $106,000. Advisors Asset Management Inc. boosted its stake in BioMarin Pharmaceutical by 13.6% during the 1st quarter. Advisors Asset Management Inc. now owns 10,382 shares of the biotechnology company’s stock worth $907,000 after purchasing an additional 1,240 shares during the period. Finally, Canada Pension Plan Investment Board grew its holdings in shares of BioMarin Pharmaceutical by 12.6% during the first quarter. Canada Pension Plan Investment Board now owns 312,638 shares of the biotechnology company’s stock worth $27,306,000 after buying an additional 34,867 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.